Recce Pharmaceuticals

Corporate Governance

Why Invest

News and Media

Announcements

Titillium Web

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

qKiEyDal-30630212.mp4

This webinar explores what it takes for ASX-listed companies to get new health care developments – whether that be drugs, apps or other technologies – through the complexities of Australia’s Therapeutic Goods Association approvals process.

Watch Recce's Chief Scientific Officer and co-inventor Michele Dilizia speak about Recce's progress with the advanced testing of a patented antibiotic called R327. It’s being trialled in Australia and abroad for treating sepsis, UTIs and burns. 

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market